Scientists unveil surprising human vs. mouse differences in a major cancer immunotherapy target
Since its discovery in the 1990s, programmed cell death protein 1 (PD-1) has been regarded as a leading target in cancer treatments. A checkpoint receptor that often resides on the surface of immune system cells, the PD-1 molecule works as a type of “off” switch that keeps immune cells from attacking other cells…
Read More
0
